<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>16554</routedMedId>
		<routedMedName>Remicade intravenous</routedMedName>
		<routedGenericName>infliximab intravenous</routedGenericName>
		<etcIds>
			<etc_id>5708</etc_id>
		</etcIds>
		<medIds>
			<medId>197780</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<fqn>Ankylosing Spondylitis</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2827</icd9>
			<symbolic>Remicade-AnkylosingSpondylitis</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype_name>
				<name></name>
			</subtype_name>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Rheumatology</name>
					<code>207RR0500X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name></subtype_name>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
		  <concurrentTherapyExclusion>
		    <criteriaSet>  
		      <excludedTherapy>
		        <treatment>  
		          <treatmentLine> 
		            <option>WITH</option>
		            <interventionType>drug</interventionType>
		            <name/>
		            <codeValues/>
		            <selectedListName/>
		            <selectedListClassCode/>
		          </treatmentLine>
		        </treatment>
		      </excludedTherapy>
		    </criteriaSet>
		  </concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Remicade (infliximab) lyophilized concentrate for injection. Physician Prescribing Information [Internet] Janssen Biotech, Inc. 2013 Nov Accessed at: http://www.remicade.com/.</reference>
				<reference>Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology 2012;51(8):1378-87. DOI: 10.1093/rheumatology/kes026.</reference>
				<reference>Machado MA, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatology International 2013;33(9):199-213. DOI: 10.1007/s00296-013-2772-6.</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Braun J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Annals of the Rheumatic Diseases 2008;67(3):340-5. DOI: 10.1136/ard.2007.075879.</reference>
				<reference>Braun J, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 2011;70(6):896-904. DOI: 10.1136/ard.2011.151027.</reference>
				<reference>van der Heijde D, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases 2011;70(6):905-8. DOI: 10.1136/ard.2011.151563</reference>
				<reference>Khan MA, Ozgocmen S. Ankylosing spondylitis. Physicians' Information and Education Resource [Internet] American College of Physicians. 2013 May Accessed at: http://pier.acponline.org/.</reference>
				<reference>Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12(2):193-207. DOI: 10.1517/14712598.2012.646986.</reference>
				<reference>Perez-Alvarez R, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90(6):359-71. DOI: 10.1097/MD.0b013e3182380a76.</reference>
				<reference>Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. Journal of the American Academy of Dermatology 2012;67(6):1349-61. DOI: 10.1016/j.jaad.2012.04.036.</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
				<reference>Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology 2011;7(3):329-40. DOI: 10.1586/eci.11.6.</reference>
				<reference>Sivamani RK, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinical Reviews in Allergy and Immunology 2013;44(2):121-40. DOI: 10.1007/s12016-012-8301-7.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Behcet's Disease</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<?oxy_comment_start author="paulnguyen" timestamp="20150128T111207-0800" comment="C: 406 is the DXID from the synonym table (RFMLSYN0_DXID_SYN) and covers other autoimmune disorders.

802 is the DXID for Behcet&apos;s disease associated with ICD10 code M35.2.  The ICD10 code description is for Behcet&apos;s disease but the DXID description is for Autoimmune Disease."?>
			<icd9><?oxy_comment_end?>22.406</icd9>
			<symbolic>Remicade-Behcet</symbolic>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Ophthalmologist</name>
					<code>207W00000X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Hatemi G, et al. EULAR recommendations for the management of Behcet disease. Annals of the Rheumatic Diseases 2008;67(12):1656-62. DOI: 10.1136/ard.2007.080432</reference>
				<reference>Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behcet's Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Archives of Ophthalmology 2012;130(5):592-8. DOI: 10.1001/archophthalmol.2011.2698.</reference>
				<reference>Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Seminars in Arthritis and Rheumatism 2011;41(1):61-70. DOI: 10.1016/j.semarthrit.2010.09.002.</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12(2):193-207. DOI: 10.1517/14712598.2012.646986.</reference>
				<reference>Perez-Alvarez R, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90(6):359-71. DOI: 10.1097/MD.0b013e3182380a76.</reference>
				<reference>Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. Journal of the American Academy of Dermatology 2012;67(6):1349-61. DOI: 10.1016/j.jaad.2012.04.036.</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
				<reference>Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology 2011;7(3):329-40. DOI: 10.1586/eci.11.6.</reference>
				<reference>Sivamani RK, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinical Reviews in Allergy and Immunology 2013;44(2):121-40. DOI: 10.1007/s12016-012-8301-7.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives/>
		</diagnosis>
		<diagnosis>
			<fqn>Uveitis</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.1191</icd9>
			<symbolic>Remicade-Uveitis</symbolic>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Ophthalmologist</name>
					<code>207W00000X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Pato E, et al. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Seminars in Arthritis and Rheumatism 2011;40(4):314-23. DOI: 10.1016/j.semarthrit.2010.05.008.</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12(2):193-207. DOI: 10.1517/14712598.2012.646986.</reference>
				<reference>Perez-Alvarez R, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90(6):359-71. DOI: 10.1097/MD.0b013e3182380a76.</reference>
				<reference>Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. Journal of the American Academy of Dermatology 2012;67(6):1349-61. DOI: 10.1016/j.jaad.2012.04.036.</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
				<reference>Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology 2011;7(3):329-40. DOI: 10.1586/eci.11.6.</reference>
				<reference>Sivamani RK, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinical Reviews in Allergy and Immunology 2013;44(2):121-40. DOI: 10.1007/s12016-012-8301-7.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives/>
		</diagnosis>
		<diagnosis>
			<fqn>Crohn's Disease-moderate to severe</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>6</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2084</icd9>
			<symbolic>Remicade-CrohnsDisease</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name>moderate to severe</name>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Pediatric Gastroenterology</name>
					<code>2080P0206X</code>
				</prescriber>
				<prescriber>
					<name>Gastroenterology</name>
					<code>207RG0100X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Remicade (infliximab) lyophilized concentrate for injection. Physician Prescribing Information [Internet] Janssen Biotech, Inc. 2013 Nov Accessed at: http://www.remicade.com/.</reference>
				<reference>D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nature Reviews. Gastroenterology &amp; Hepatology 2010;7(2):86-92. DOI: 10.1038/nrgastro.2009.222.</reference>
				<reference>Infliximab (review) and adalimumab for the treatment of Crohn's disease. Technical Appraisal 187 [Internet] National Institute for Health and Clinical Excellence. 2010 May Accessed at: http://guidance.nice.org.uk/.</reference>
				<reference>Dretzke J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technology Assessment 2011;15(6):1-244. DOI: 10.3310/hta15060.</reference>
				<reference>Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008, (verified by Cochrane 2009 Apr), Issue 1. Art. No.: CD006893. DOI: 10.1002/14651858.CD006893.</reference>
				<reference>Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. American Journal of Gastroenterology 2011;106(4):644-59, quiz 660. DOI: 10.1038/ajg.2011.73.</reference>
				<reference>Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clinical Gastroenterology and Hepatology 2008;6(6):644-53. DOI: 10.1016/j.cgh.2008.03.014.</reference>
				<reference>Crohn's disease: management in adults, children and young people. NICE Clinical Guideline CG152 [Internet] National Institute for Clinical Excellence. 2012 Oct Accessed at: http://guidance.nice.org.uk/.</reference>
				<reference>Dignass A, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's &amp; Colitis 2010;4(1):28-62. DOI: 10.1016/j.crohns.2009.12.002.</reference>
				<reference>Orlando A, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease 2011;43(1):1-20. DOI: 10.1016/j.dld.2010.07.010.</reference>
				<reference>D'Haens GR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? American Journal of Gastroenterology 2011;106(2):199-212; quiz 213. DOI: 10.1038/ajg.2010.392.</reference>
				<reference>Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. American Journal of Gastroenterology 2009;104(2):465-83; quiz 464, 484. DOI: 10.1038/ajg.2008.168.</reference>
				<reference>Fasci Spurio F, Aratari A, Margagnoni G, Doddato MT, Papi C. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? Journal of Gastrointestinal and Liver Diseases 2012;21(1):67-73.</reference>
				<reference>D'Haens G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371(9613):660-7. DOI: 10.1016/S0140-6736(08)60304-9.</reference>
				<reference>Colombel JF, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine 2010;362(15):1383-95. DOI: 10.1056/NEJMoa0904492.</reference>
				<reference>Oussalah A, Danese S, Peyrin-Biroulet L. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Current Drug Targets 2010;11(2):156-75.</reference>
				<reference>Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nature Reviews. Gastroenterology &amp; Hepatology 2010;7(2):79-85. DOI: 10.1038/nrgastro.2009.220.</reference>
				<reference>Kim MJ, Lee JS, Lee JH, Kim JY, Choe YH. Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies. Acta Paediatrica 2011;100(3):451-5. DOI: 10.1111/j.1651-2227.2010.01938.x.</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12(2):193-207. DOI: 10.1517/14712598.2012.646986.</reference>
				<reference>Perez-Alvarez R, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90(6):359-71. DOI: 10.1097/MD.0b013e3182380a76.</reference>
				<reference>Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. Journal of the American Academy of Dermatology 2012;67(6):1349-61. DOI: 10.1016/j.jaad.2012.04.036.</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
				<reference>Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology 2011;7(3):329-40. DOI: 10.1586/eci.11.6.</reference>
				<reference>Sivamani RK, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinical Reviews in Allergy and Immunology 2013;44(2):121-40. DOI: 10.1007/s12016-012-8301-7.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Moderate to Severe Plaque Psoriasis</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.13956</icd9>
			<symbolic>Remicade-PlaquePsoriasis</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Dermatology</name>
					<code>207N00000X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Remicade (infliximab) lyophilized concentrate for injection. Physician Prescribing Information [Internet] Janssen Biotech, Inc. 2013 Nov Accessed at: http://www.remicade.com/. [created 1008; accessed 2013 Dec 2]</reference>
				<reference>Infliximab for the treatment of adults with psoriasis. NICE Technology Appraisal TA134 [Internet] National Institute for Health and Clinical Excellence. 2008 Jan Accessed at: http://guidance.nice.org.uk/.</reference>
				<reference>Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology (Basil, Switzerland) 2009;219(3):209-18. DOI: 10.1159/000233234.</reference>
				<reference>Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. British Journal of Dermatology 2012;166(1):179-88. DOI: 10.1111/j.1365-2133.2011.10583.x.</reference>
				<reference>Lee S, et al. Biologic and nonbiologic systemic agents and phototherapy for treatment of chronic plaque psoriasis. Comparative Effectiveness Review #85. AHRQ Publication No. 12(13)-EHC144-EF [Internet] Agency for Healthcare Research and Quality (AHRQ). 2012 Nov Accessed at: http://www.effectivehealthcare.ahrq.gov/.</reference>
				<reference>Lucka TC, et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. Journal of the European Academy of Dermatology and Venereology: JEADV. 2012;26(11):1331-44. DOI: 10.1111/j.1468-3083.2012.04492.x.</reference>
				<reference>Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. British Journal of Dermatology 2008;159(3):513-26. DOI: 10.1111/j.1365-2133.2008.08732.x.</reference>
				<reference>American Academy of Dermatology Work Group, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. Journal of the American Academy of Dermatology 2011;65(1):137-74. DOI: 10.1016/j.jaad.2010.11.055.</reference>
				<reference>Hsu S, et al. Consensus guidelines for the management of plaque psoriasis. Archives of Dermatology 2012;148(1):95-102. DOI: 10.1001/archdermatol.2011.1410.</reference>
				<reference>Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology 2010;62(1):114-35. DOI: 10.1016/j.jaad.2009.08.026.</reference>
				<reference>Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. Journal of the American Academy of Dermatology 2009;60(4):643-59. DOI: 10.1016/j.jaad.2008.12.032.</reference>
				<reference>Leman J, Burden AD. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. British Journal of Dermatology 2012;167 Suppl 3:12-20. DOI: 10.1111/j.1365-2133.2012.11209.x.</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12(2):193-207. DOI: 10.1517/14712598.2012.646986.</reference>
				<reference>Perez-Alvarez R, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90(6):359-71. DOI: 10.1097/MD.0b013e3182380a76.</reference>
				<reference>Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. Journal of the American Academy of Dermatology 2012;67(6):1349-61. DOI: 10.1016/j.jaad.2012.04.036.</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
				<reference>Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology 2011;7(3):329-40. DOI: 10.1586/eci.11.6.</reference>
				<reference>Sivamani RK, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinical Reviews in Allergy and Immunology 2013;44(2):121-40. DOI: 10.1007/s12016-012-8301-7.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Psoriatic Arthritis-moderate to severe</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2682</icd9>
			<symbolic>Remicade-PsoriaticArthritis</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Rheumatology</name>
					<code>207RR0500X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Remicade (infliximab) lyophilized concentrate for injection. Physician Prescribing Information [Internet] Janssen Biotech, Inc. 2013 Nov Accessed at: http://www.remicade.com/. [created 1008; accessed 2013 Dec 2]</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Ash Z, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases 2012;71(3):319-26. DOI: 10.1136/ard.2011.150995.</reference>
				<reference>Gossec L, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases 2012;71(1):4-12. DOI: 10.1136/annrheumdis-2011-200350.</reference>
				<reference>Atteno M, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clinical Rheumatology 2010;29(4):399-403. DOI: 10.1007/s10067-009-1340-7.</reference>
				<reference>Salvarani C, et al. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clinical and Experimental Rheumatology 2011;29(3 Suppl 66):S28-41.</reference>
				<reference>Gottlieb A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. Journal of the American Academy of Dermatology 2008;58(5):851-64. DOI: 10.1016/j.jaad.2008.02.040.</reference>
				<reference>Ritchlin CT, et al. Treatment recommendations for psoriatic arthritis. Annals of the Rheumatic Diseases 2009;68(9):1387-94. DOI: 10.1136/ard.2008.094946.</reference>
				<reference>Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12(2):193-207. DOI: 10.1517/14712598.2012.646986.</reference>
				<reference>Perez-Alvarez R, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90(6):359-71. DOI: 10.1097/MD.0b013e3182380a76.</reference>
				<reference>Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. Journal of the American Academy of Dermatology 2012;67(6):1349-61. DOI: 10.1016/j.jaad.2012.04.036.</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
				<reference>Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology 2011;7(3):329-40. DOI: 10.1586/eci.11.6.</reference>
				<reference>Sivamani RK, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinical Reviews in Allergy and Immunology 2013;44(2):121-40. DOI: 10.1007/s12016-012-8301-7.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Rheumatoid Arthritis-moderate to severe</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2805</icd9>
			<symbolic>Remicade-RA</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Rheumatologist</name>
					<code>207RR0500X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name>Remicade</name>
								<codeValues>01.15555</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name>methotrexate sodium</name>
								<codeValues>01.5506</codeValues>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>rtherapy</rating>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name>Remicade</name>
								<codeValues>01.15555</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name>methotrexate sodium</name>
								<codeValues>01.5506</codeValues>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Remicade (infliximab) lyophilized concentrate for injection. Physician Prescribing Information [Internet] Janssen Biotech, Inc. 2013 Nov Accessed at: http://www.remicade.com/. [created 1008; accessed 2013 Dec 2]</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Nam JL, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Annals of the Rheumatic Diseases 2010;69(6):976-86. DOI: 10.1136/ard.2009.126573.</reference>
				<reference>Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases 2010;69(6):964-75. DOI: 10.1136/ard.2009.126532.</reference>
				<reference>Donahue KE, et al. Drug therapy for rheumatoid arthritis in adults: an update. Comparative Effectiveness Review #55. AHRQ Publication No. 12-EHC025-EF [Internet] Agency for Healthcare Research and Quality (AHRQ). 2012 Jun Accessed at: http://www.ahrq.gov. [created 2007; accessed 2013 Oct 4]</reference>
				<reference>Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 2012;7(1):e30275. DOI: 10.1371/journal.pone.0030275.</reference>
				<reference>Hetland ML, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis and Rheumatism 2010;62(1):22-32. DOI: 10.1002/art.27227.</reference>
				<reference>Lopez-Olivo MA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. Journal of the American Medical Association 2012;308(9):898-908. DOI: 10.1001/2012.jama.10857.</reference>
				<reference>Bykerk VP, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Journal of Rheumatology 2012;39(8):1559-82. DOI: 10.3899/jrheum.110207.</reference>
				<reference>Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376(9746):1094-108. DOI: 10.1016/S0140-6736(10)60826-4.</reference>
				<reference>Miller AV, Ranatunga SK. Immunotherapies in rheumatologic disorders. Medical Clinics of North America 2012;96(3):475-96, ix-x. DOI: 10.1016/j.mcna.2012.04.003.</reference>
				<reference>Malottki K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technology Assessment 2011;15(14):1-278. DOI: 10.3310/hta15140.</reference>
				<reference>Remy A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clinical and Experimental Rheumatology 2011;29(1):96-103.</reference>
				<reference>Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology 2012;51(12):2252-61. DOI: 10.1093/rheumatology/kes217.</reference>
				<reference>Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor a inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Annals of the Rheumatic Diseases 2012;71(8):1303-8. DOI: 10.1136/annrheumdis-2011-200490.</reference>
				<reference>Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Annals of the Rheumatic Diseases 2010;69(7):1298-304. DOI: 10.1136/ard.2009.118307.</reference>
				<reference>Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12(2):193-207. DOI: 10.1517/14712598.2012.646986.</reference>
				<reference>Perez-Alvarez R, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90(6):359-71. DOI: 10.1097/MD.0b013e3182380a76.</reference>
				<reference>Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. Journal of the American Academy of Dermatology 2012;67(6):1349-61. DOI: 10.1016/j.jaad.2012.04.036.</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
				<reference>Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology 2011;7(3):329-40. DOI: 10.1586/eci.11.6.</reference>
				<reference>Sivamani RK, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinical Reviews in Allergy and Immunology 2013;44(2):121-40. DOI: 10.1007/s12016-012-8301-7.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Ulcerative Collitis-moderate to severe</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>6</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2089</icd9>
			<symbolic>Remicade-UC</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name>moderate to severe</name>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Pediatric Gastroenterology</name>
					<code>2080P0206X</code>
				</prescriber>
				<prescriber>
					<name>Gastroenterology</name>
					<code>207RG0100X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Remicade (infliximab) lyophilized concentrate for injection. Physician Prescribing Information [Internet] Janssen Biotech, Inc. 2013 Nov Accessed at: http://www.remicade.com/.</reference>
				<reference>D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nature Reviews. Gastroenterology &amp; Hepatology 2010;7(2):86-92. DOI: 10.1038/nrgastro.2009.222.</reference>
				<reference>Oussalah A, Danese S, Peyrin-Biroulet L. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Current Drug Targets 2010;11(2):156-75.</reference>
				<reference>Orlando A, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease 2011;43(1):1-20. DOI: 10.1016/j.dld.2010.07.010.</reference>
				<reference>D'Haens GR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? American Journal of Gastroenterology 2011;106(2):199-212; quiz 213. DOI: 10.1038/ajg.2010.392.</reference>
				<reference>Turner D, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. Journal of Pediatric Gastroenterology and Nutrition 2012;55(3):340-61. DOI: 10.1097/MPG.0b013e3182662233.</reference>
				<reference>Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflammatory Bowel Diseases 2011;17(1):440-9. DOI: 10.1002/ibd.21383.</reference>
				<reference>Hyams J, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clinical Gastroenterology and Hepatology 2012;10(4):391-9.e1. DOI: 10.1016/j.cgh.2011.11.026.</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12(2):193-207. DOI: 10.1517/14712598.2012.646986.</reference>
				<reference>Perez-Alvarez R, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90(6):359-71. DOI: 10.1097/MD.0b013e3182380a76.</reference>
				<reference>Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. Journal of the American Academy of Dermatology 2012;67(6):1349-61. DOI: 10.1016/j.jaad.2012.04.036.</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
				<reference>Salgado E, Gomez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology 2011;7(3):329-40. DOI: 10.1586/eci.11.6.</reference>
				<reference>Sivamani RK, et al. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clinical Reviews in Allergy and Immunology 2013;44(2):121-40. DOI: 10.1007/s12016-012-8301-7.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Hidrandenitis Suppurativa-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>12.L73.2</icd9>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. Journal of the American Academy of Dermatology 2010;62(2):205-17. DOI: 10.1016/j.jaad.2009.06.050.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Juvenile Idiopathic Arthritis-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.14082</icd9>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Kemper AR, et al. Disease-modifying antirheumatic drugs (DMARDs) in children with juvenile idiopathic arthritis (JIA). Effective Health Care Program comparative effectiveness review number 28. AHRQ Publication No. 11-EHC039-EF [Internet] Agency for Healthcare Quality and Research. 2011 Sep Accessed at: http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Sarcoidosis-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>12.D86</icd9>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Maneiro JR, Salgado E, Gomez-Reino JJ, Carmona L, BIOBADASER Study Group. Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review. Seminars in Arthritis and Rheumatism 2012;42(1):89-103. DOI: 10.1016/j.semarthrit.2011.12.006.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Sjogren Syndrome-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.4386</icd9>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. Journal of the American Medical Association 2010;304(4):452-60. DOI: 10.1001/jama.2010.1014.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Systemic Sclerosis-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>12.M34</icd9>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. Journal of Rheumatology 2011;38(2):289-96. DOI: 10.3899/jrheum.100361.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
	</lists>
</paload>
